series-a
Stage
1
Investors
About
Remepy develops hybrid drugs that combine pharmaceutical molecules with AI-driven digital protocols to improve clinical outcomes, primarily targeting diseases such as Parkinson’s Disease with therapies like Hybridopa, which integrates levodopa medication and software-based interventions.
Explore Remepy's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.